Trial · NCT05061693
Adverse events1,236
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,236
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Aspergillus test positive | Investigations | Placebo | 0 | 37 | 0 |
| other | Aspergillus test positive | Investigations | Povorcitinib 15 mg | 0 | 36 | 0 |
| other | Aspergillus test positive | Investigations | Povorcitinib 45 mg | 0 | 35 | 0 |
| other | Aspergillus test positive | Investigations | Povorcitinib 75 mg | 0 | 37 | 0 |
| other | Aspergillus test positive | Investigations | Placebo to Povorcitinib 45 mg | 0 | 1 | 0 |
| other | Aspergillus test positive | Investigations | Povorcitinib 15 mg to 45 mg | 0 | 4 | 0 |
| other | Aspergillus test positive | Investigations | Povorcitinib 45 mg to 45 mg | 0 | 8 | 0 |
| other | Aspergillus test positive | Investigations | Povorcitinib 75 mg to 45 mg | 1 | 15 | 1 |
| other | Aspergillus test positive | Investigations | Placebo to Povorcitinib 75 mg | 0 | 30 | 0 |
| other | Aspergillus test positive | Investigations | Povorcitinib 15 mg to 75 mg | 0 | 25 | 0 |
| other | Aspergillus test positive | Investigations | Povorcitinib 45 mg to 75 mg | 0 | 23 | 0 |
| other | Aspergillus test positive | Investigations | Povorcitinib 75 mg to 75 mg | 0 | 18 | 0 |
| other | Asthma | Respiratory, thoracic and mediastinal disorders | Placebo | 0 | 37 | 0 |
| other | Asthma | Respiratory, thoracic and mediastinal disorders | Povorcitinib 15 mg | 0 | 36 | 0 |
| other | Asthma | Respiratory, thoracic and mediastinal disorders | Povorcitinib 45 mg | 0 | 35 | 0 |
| other | Asthma | Respiratory, thoracic and mediastinal disorders | Povorcitinib 75 mg | 1 | 37 | 1 |
| other | Asthma | Respiratory, thoracic and mediastinal disorders | Placebo to Povorcitinib 45 mg | 0 | 1 | 0 |
| other | Asthma | Respiratory, thoracic and mediastinal disorders | Povorcitinib 15 mg to 45 mg | 0 | 4 | 0 |
| other | Asthma | Respiratory, thoracic and mediastinal disorders | Povorcitinib 45 mg to 45 mg | 0 | 8 | 0 |
| other | Asthma | Respiratory, thoracic and mediastinal disorders | Povorcitinib 75 mg to 45 mg | 0 | 15 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05061693/events